SPHINGOTEC GROUP


COMBINING INNOVATIVE BIOMARKERS WITH OUTSTANDING TECHNOLOGY

LATEST NEWS


Sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)



Learn more

Sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology.



Learn more

Endothelial disruption: Rapid translation from bench to bedside.



Learn more

Sphingotec raises €20 million from HBM and Wellington Partners.



Learn more